Vetoquinol entered 2026 with a familiar strategic message: in a more volatile operating environment, scale matters less than product mix, execution and resilience.

In its latest company update, the France-based animal health group reported 2025 sales of EUR 525.7 million, which it rounded to EUR 526 million, up 0.2% at constant exchange rates but down 2.5% on a reported basis due to unusually strong currency headwinds. The company said negative foreign-exchange effects reached EUR 14.8 million during the year, weighing on reported performance outside Europe. 

The stronger signal for the market came from Vetoquinol’s Essential Products portfolio, which generated EUR 334.5 million in 2025 sales, or EUR 334 million on the company’s rounded basis. That business grew 4.1% at constant exchange rates and 2.1% on a reported basis, reinforcing the group’s long-running strategy of concentrating on higher-priority brands with broader international potential. 

For animal health investors and industry watchers, that matters because it shows how companies are trying to protect growth even when exchange rates and portfolio clean-ups distort the headline numbers. Vetoquinol said its 2025 performance was also affected by a EUR 9.7 million impact from the continued simplification of its Complementary product ranges. Excluding both the negative currency effect and that portfolio rationalisation, the company said full-year sales were up 2.1% versus 2024. 

Operationally, Vetoquinol also pointed to progress in bringing manufacturing of its parasiticide range in-house. The company said that internalisation process, linked to products acquired in 2020, was completed during 2025 and helped support a stronger fourth quarter for Essential Products. 

From a business perspective, the update underlines a broader animal health trend: companies with focused portfolios and tighter manufacturing control are positioning themselves to defend margins and sharpen category leadership, even when macro conditions remain unpredictable. Vetoquinol describes itself as active across both pets and farm animals, with its latest key-figures page showing a revenue mix of 70% companion animals and 30% farm animals. 

The company’s next major financial checkpoint is its 2025 annual results, scheduled for March 27, 2026, according to Vetoquinol’s investor agenda. Until then, the sales release suggests a business still relying on strategic brands to carry growth in a market where reported performance can be heavily shaped by factors beyond underlying demand. 

Follow the link to read the article from Vetoquinol.